PARK CIRCLE Co maintained its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 10,000 shares of the company’s stock at the end of the second quarter. PARK CIRCLE Co’s holdings in Teva Pharmaceutical Industries Limited were worth $332,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in TEVA. Renaissance Technologies LLC increased its stake in Teva Pharmaceutical Industries Limited by 122.4% in the first quarter. Renaissance Technologies LLC now owns 4,817,763 shares of the company’s stock worth $154,602,000 after buying an additional 2,651,900 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its stake in Teva Pharmaceutical Industries Limited by 405,409.9% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,435,505 shares of the company’s stock worth $46,065,000 after buying an additional 1,435,151 shares during the period. Sei Investments Co. increased its stake in Teva Pharmaceutical Industries Limited by 103.6% in the second quarter. Sei Investments Co. now owns 1,721,466 shares of the company’s stock worth $57,188,000 after buying an additional 875,789 shares during the period. Ameriprise Financial Inc. increased its stake in Teva Pharmaceutical Industries Limited by 142.2% in the first quarter. Ameriprise Financial Inc. now owns 1,288,571 shares of the company’s stock worth $41,349,000 after buying an additional 756,441 shares during the period. Finally, Commerzbank Aktiengesellschaft FI increased its stake in Teva Pharmaceutical Industries Limited by 370.6% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 929,084 shares of the company’s stock worth $29,814,000 after buying an additional 731,666 shares during the period. 56.87% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 15.93 on Tuesday. The company’s market capitalization is $16.18 billion. Teva Pharmaceutical Industries Limited has a one year low of $15.72 and a one year high of $52.66. The company has a 50-day moving average price of $25.37 and a 200-day moving average price of $30.35.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same quarter last year, the company posted $1.25 earnings per share. The company’s revenue was up 12.9% compared to the same quarter last year. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be given a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 2.13%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -15.36%.

TRADEMARK VIOLATION NOTICE: “PARK CIRCLE Co Has $332,000 Position in Teva Pharmaceutical Industries Limited (TEVA)” was reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.watchlistnews.com/park-circle-co-has-332000-position-in-teva-pharmaceutical-industries-limited-teva/1529775.html.

A number of research analysts have commented on TEVA shares. TheStreet cut Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a research note on Friday. Jefferies Group LLC restated a “hold” rating and set a $26.00 price objective (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Deutsche Bank AG restated a “buy” rating and set a $28.00 price objective (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Sanford C. Bernstein cut Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $42.00 to $28.00 in a research note on Friday, August 4th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective (down previously from $31.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Four analysts have rated the stock with a sell rating, nineteen have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries Limited currently has a consensus rating of “Hold” and an average price target of $35.06.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.